Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Completed 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1Gynecologic 1Genitourinary 1

Conditions

Lymphoma, T-Cell, Peripheral 6Lymphoma, T-Cell 5Recurrence 4Lymphoma 4Lymphoma, Non-Hodgkin 3Lymphoma, Large-Cell, Anaplastic 3Immunoblastic Lymphadenopathy 3Neoplasm Metastasis 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Hodgkin Disease 2Esophageal Squamous Cell Carcinoma 2Adenocarcinoma Of Esophagus 2Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Subcutaneous panniculitis-like T-cell lymphoma 1Stomach Neoplasms 1Smoking 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Mycosis Fungoides 1Lymphoproliferative Disorders 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1

Interventions

Dexamethasone 43Cyclophosphamide 38fludarabine phosphate 27Cytarabine 26Rituximab 24Methotrexate 21Lenalidomide 21Bortezomib 21Calcium Dobesilate 20fludarabine 19Peripheral Blood Stem Cell Transplantation 19Whole-Body Irradiation 16Mycophenolic Acid 16pembrolizumab 15Gemcitabine 15Etoposide 15pomalidomide 14Melphalan 14Vincristine 13Filgrastim 13Busulfan 13Tacrolimus 12Cyclosporine 12Carboplatin 12Paclitaxel 11carfilzomib 10durvalumab 9Doxorubicin 9Cetuximab 9Brentuximab Vedotin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Recurrence × 10-propargyl-10-deazaaminopterin × Clear all
NCT00998946 2021-11-05

Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Spectrum Pharmaceuticals, Inc

Phase 2 Completed
29 enrolled 8 charts
Lymphoid

Recurrence, Lymphoma, B-Cell

NCT00481871 2020-01-07

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

Acrotech Biopharma Inc.

Phase 1/2 Completed
119 enrolled 13 charts
LymphoidOther hematologic neoplasm

Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Recurrence, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

NCT00722553 2019-12-17

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

Acrotech Biopharma Inc.

Phase 2 Completed
30 enrolled 12 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Neoplasm Metastasis, Recurrence

NCT01188876 2018-01-19

Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer

Massachusetts General Hospital

Phase 1/2 Completed
50 enrolled 15 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡